Your browser doesn't support javascript.
loading
Genetic analysis and clinical picture of severe congenital neutropenia in Israel.
Lebel, Asaf; Yacobovich, Joanne; Krasnov, Tanya; Koren, Ariel; Levin, Carina; Kaplinsky, Chaim; Ravel-Vilk, Shoshana; Laor, Ruth; Attias, Dina; Ben Barak, Ayelet; Shtager, Dalia; Stein, Jerry; Kuperman, Amir; Miskin, Hagit; Dgany, Orly; Giri, Neelam; Alter, Blanche P; Tamary, Hannah.
Afiliación
  • Lebel A; Department of Pediatrics B, Schneider Children's Medical Center of Israel, Petach Tikva, Israel and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Pediatr Blood Cancer ; 62(1): 103-8, 2015 Jan.
Article en En | MEDLINE | ID: mdl-25284454
ABSTRACT

BACKGROUND:

The relative frequency of mutated genes among patients with severe congenital neutropenia (SCN) may differ between various ethnic groups. To date, few population-based genetic studies have been reported. This study describes the genetic analysis of 32 Israeli patients with SCN. PROCEDURES Clinical data were retrieved from the prospective Israeli Inherited Bone Marrow Failure Registry. Recruitment included living and deceased patients who were diagnosed between 1982 and 2012, for whom molecular diagnosis was performed. ELANE, HAX1 and G6PC3 genes were sequenced in all patients, and GFI-1 and WAS genes were sequenced if other genes were wildtype.

RESULTS:

Eleven patients (34%) had heterozygous mutations in ELANE (10 kindreds), eight (25%) had homozygous mutations in G6PC3 (5 kindreds) and 13 (41%) had no detected mutations. No patients had mutations in HAX1 or WAS. Four of the eight patients with G6PC3 mutations had congenital anomalies. The probability of survival for all patients was 50% at age of 18. Deaths were mainly due to sepsis (5 patients, 4/5 not responding to G-CSF, none with G6PC3 mutation). Two patients developed acute myelogenous leukemia (AML) and one myelodysplastic syndrome (MDS), none with G6PC3 mutation.

CONCLUSIONS:

We found a unique pattern of SCN mutations in Israel with homozygous G6PC3 mutations in eight (25%) patients, the highest frequency described so far. HAX1 mutations, reported mainly in Sweden and Iran, were absent. Patients with G6PC3 mutations had congenital anomalies, appeared to have a better response to G-CSF, and so far have not developed AML or MDS.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Pruebas Genéticas / Glucosa-6-Fosfatasa / Proteínas Adaptadoras Transductoras de Señales / Mutación / Neutropenia Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies País/Región como asunto: Asia Idioma: En Revista: Pediatr Blood Cancer Asunto de la revista: HEMATOLOGIA / NEOPLASIAS / PEDIATRIA Año: 2015 Tipo del documento: Article País de afiliación: Israel

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Pruebas Genéticas / Glucosa-6-Fosfatasa / Proteínas Adaptadoras Transductoras de Señales / Mutación / Neutropenia Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies País/Región como asunto: Asia Idioma: En Revista: Pediatr Blood Cancer Asunto de la revista: HEMATOLOGIA / NEOPLASIAS / PEDIATRIA Año: 2015 Tipo del documento: Article País de afiliación: Israel